In conclusion, we constructed a five DEGs (CCNB2, CDK1, DTL, GMNN, and UBE2C)-based prognostic signature for ACC and first identified GMNN as a novel tumor biomarker for predicting the malignant progression, mitotane efficacy, and prognosis of ACC. This evidence concerns the gene CDK1 and adrenal cortex carcinoma.